← Every company
Nektar Therapeutics Patents
What Nektar Therapeutics has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
NKTR on carbonthat →Filings on file
8
Granted
0
Still pending
8
Filed under
2 names
8 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| POLYMER ENGINEERED FORMS OF COLONY STIMULATING FACTOR-1 (CSF-1) HAVING REDUCED RECEPTOR AFFINITY AND METHODS OF USEFiled as NEKTAR THERAPEUTICS2025-09-17SAUL KIVIMAE | pending |
| ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2) ANTIBODIES AND METHODS OF USEFiled as NEKTAR THERAPEUTICS2025-05-28DAMON JUSTIN HAMEL | pending |
| CONJUGATES OF AN IL-2 MOIETY AND A POLYMERA61K 47/60, A61K 38/2013, C07K 14/55, A61K 47/56, A61P 37/02, A61P 37/04, A61P 17/00, A61P 19/02, A61P 31/14, A61P 31/18, A61P 35/02, A61P 37/08, Y02A 50/30, A61P 29/00, A61P 35/00, A61K 47/12, A61K 47/26Filed as Nektar Therapeutics2025-02-06Mary J. Bossard | pending |
| POLYMER ENGINEERED FORMS OF COLONY STIMULATING FACTOR-1 (CSF-1) HAVING REDUCED RECEPTOR AFFINITY AND METHODS OF USEFiled as Nektar Therapeutics2024-11-15Saul Kivimae | pending |
| POLYMER ENGINEERED FORMS OF COLONY STIMULATING FACTOR-1 (CSF-1) HAVING REDUCED RECEPTOR AFFINITY AND METHODS OF USEFiled as Nektar Therapeutics2024-11-06Saul Kivimae | pending |
| POLYMER ENGINEERED FORMS OF COLONY STIMULATING FACTOR-1 (CSF-1) HAVING REDUCED RECEPTOR AFFINITY AND METHODS OF USEFiled as Nektar Therapeutics2024-09-18Saul Kivimae | pending |
| LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONISTS AND RELATED IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODSA61K 47/60, A61P 35/04, A61P 35/00, A61K 38/00, A61K 38/2086, C07K 14/5443, C07K 14/7156Filed as Nektar Therapeutics2024-06-06Peter Benedict Kirk | pending |
| POLYMER ENGINEERED FORMS OF INTERFERON-GAMMA AND METHODS OF USEC07K 14/57, A61K 47/60, A61P 35/00, A61K 38/217, A61K 45/06Filed as Nektar Therapeutics2024-01-11Deborah H. Charych | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on NKTR
Company overviewEverything on NKTR in one place, with the price.SEC filingsWhat NKTR's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat NKTR's own officers and directors buy and sell.Executive payWhat NKTR awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in NKTR.Funds holding itWhich funds and ETFs hold NKTR, and how big a bet.